{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:02:39Z","timestamp":1789668159305,"version":"4.0.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024157","name":"Neurelis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01007-w","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:11:52Z","timestamp":1789665112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benzodiazepines in Epilepsy: A US Perspective on Clinical Use, Pharmacology, Abuse Methods, and Public Health Considerations"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-0722","authenticated-orcid":false,"given":"Enrique","family":"Carrazana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-0917","authenticated-orcid":false,"given":"Joseph","family":"Sirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-1642","authenticated-orcid":false,"given":"John","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6681-7134","authenticated-orcid":false,"given":"Barry","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-8034","authenticated-orcid":false,"given":"Andres M.","family":"Kanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-0606","authenticated-orcid":false,"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"3","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","volume":"10","author":"GBD Epilepsy Collaborators","year":"2025","unstructured":"GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10(3):e203\u201327. https:\/\/doi.org\/10.1016\/S2468-2667(24)00302-5.","journal-title":"Lancet Public Health"},{"issue":"4","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u201382. https:\/\/doi.org\/10.1111\/epi.12550.","journal-title":"Epilepsia"},{"issue":"1","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7861\/clinmedicine.13-1-84","volume":"13","author":"JP Leach","year":"2013","unstructured":"Leach JP, Abassi H. Modern management of epilepsy. Clin Med (Lond). 2013;13(1):84\u20136. https:\/\/doi.org\/10.7861\/clinmedicine.13-1-84.","journal-title":"Clin Med (Lond)"},{"key":"1007_CR4","unstructured":"American Society of Addiction Medicine (ASAM). The joint clinical practice guideline on benzodiazepine tapering: considerations when benzodiazepine risks outweigh benefits. Rockville: ASAM; 2025."},{"issue":"9","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951\u201375. https:\/\/doi.org\/10.1007\/s40263-022-00940-2.","journal-title":"CNS Drugs"},{"issue":"2","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5863\/1551-6776-18.2.79","volume":"18","author":"LK Humphries","year":"2013","unstructured":"Humphries LK, Eiland LS. Treatment of acute seizures: is intranasal midazolam a viable option? J Pediatr Pharmacol Ther. 2013;18(2):79\u201387. https:\/\/doi.org\/10.5863\/1551-6776-18.2.79.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"8","key":"1007_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081754","volume":"10","author":"S Almohaish","year":"2021","unstructured":"Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med. 2021;10(8):1754. https:\/\/doi.org\/10.3390\/jcm10081754.","journal-title":"J Clin Med"},{"issue":"1","key":"1007_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48\u201361. https:\/\/doi.org\/10.5698\/1535-7597-16.1.48.","journal-title":"Epilepsy Curr"},{"issue":"1","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","volume":"12","author":"N Ait-Daoud","year":"2018","unstructured":"Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1):4\u201310. https:\/\/doi.org\/10.1097\/ADM.0000000000000350.","journal-title":"J Addict Med"},{"key":"1007_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.033.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.pain.2013.05.053","volume":"154","author":"SM Smith","year":"2013","unstructured":"Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287\u201396. https:\/\/doi.org\/10.1016\/j.pain.2013.05.053.","journal-title":"Pain"},{"key":"1007_CR12","unstructured":"Viatris Specialty LLC. XANAX (alprazolam). Full prescribing information. Viatris Inc; 2024."},{"issue":"5","key":"1007_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00213-014-3721-0","volume":"232","author":"CJ Reissig","year":"2015","unstructured":"Reissig CJ, Harrison JA, Carter LP, Griffiths RR. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology. 2015;232(5):871\u201383. https:\/\/doi.org\/10.1007\/s00213-014-3721-0.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136\u201342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763.","journal-title":"JAMA Psychiat"},{"key":"1007_CR15","unstructured":"Longo LP, Johnson B. Addiction: Part I. Benzodiazepines\u2014side effects, abuse risk and alternatives. Am Fam Physician. 2000;61(7):2121\u20138."},{"issue":"3","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1176\/appi.ajp.20240030","volume":"181","author":"SB Soumerai","year":"2024","unstructured":"Soumerai SB, Shahzad M, Salzman C. Setting the record straight on long-term use, dose escalation, and potential misuse of prescription benzodiazepines. Am J Psychiatry. 2024;181(3):186\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.20240030.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1007_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97\u2013106. https:\/\/doi.org\/10.1176\/appi.ps.201800321.","journal-title":"Psychiatr Serv"},{"issue":"7","key":"1007_CR18","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160\u201374. https:\/\/doi.org\/10.1111\/add.13324.","journal-title":"Addiction"},{"key":"1007_CR19","unstructured":"National Institute on Drug Abuse. Commonly abused drugs: prescriptions and OTCs. Bethesda: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services."},{"issue":"3","key":"1007_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W Loscher","year":"2020","unstructured":"Loscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606\u201338. https:\/\/doi.org\/10.1124\/pr.120.019539.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949.","journal-title":"JAMA Neurol"},{"key":"1007_CR22","doi-asserted-by":"publisher","first-page":"1081757","DOI":"10.3389\/fepid.2023.1081757","volume":"3","author":"E Trinka","year":"2023","unstructured":"Trinka E, Rainer LJ, Granbichler CA, Zimmermann G, Leitinger M. Mortality, and life expectancy in epilepsy and status epilepticus-current trends and future aspects. Front Epidemiol. 2023;3:1081757. https:\/\/doi.org\/10.3389\/fepid.2023.1081757.","journal-title":"Front Epidemiol"},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59\u201370. https:\/\/doi.org\/10.1016\/j.yebeh.2014.05.031.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1007_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11910-024-01350-1","volume":"24","author":"T Glauser","year":"2024","unstructured":"Glauser T, Becker DA, Long L, et al. Short-term impact of seizures and mitigation opportunities. Curr Neurol Neurosci Rep. 2024;24(8):303\u201314. https:\/\/doi.org\/10.1007\/s11910-024-01350-1.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1007_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2025.107507","volume":"210","author":"T Poytakangas","year":"2025","unstructured":"Poytakangas T, Basnyat P, Rainesalo S, Peltola J, Saarinen JT. Use of benzodiazepines in patients with status epilepticus requiring second-line antiseizure medication treatment. Epilepsy Res. 2025;210:107507. https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107507.","journal-title":"Epilepsy Res"},{"key":"1007_CR26","unstructured":"Better Life Recovery & Wellness. Valium addiction statistics. https:\/\/www.betterliferecovery.com\/addiction\/valium-statistics\/. Accessed 22 Sept 2025."},{"key":"1007_CR27","unstructured":"North Bethesda, Substance Abuse and Mental Health Services Administration (SAMHSA). Drug abuse warning network (DAWN) findings from drug-related emergency department visits, 2022. 2022."},{"key":"1007_CR28","unstructured":"National Institute on Drug Abuse. Drug overdose deaths: facts and figures. Bethesda: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services; 2024."},{"issue":"9","key":"1007_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3949\/ccjm.92a.25019","volume":"92","author":"J Kaur","year":"2025","unstructured":"Kaur J, Modesto-Lowe V, Chaplin MM. Benzodiazepines: caught between patient needs and guidelines. Cleve Clin J Med. 2025;92(9):531\u20135. https:\/\/doi.org\/10.3949\/ccjm.92a.25019.","journal-title":"Cleve Clin J Med"},{"issue":"1-2","key":"1007_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"JD Jones","year":"2012","unstructured":"Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1\u20132):8\u201318. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.07.004.","journal-title":"Drug Alcohol Depend"},{"key":"1007_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100302","volume":"13","author":"A Olopoenia","year":"2022","unstructured":"Olopoenia A, Camelo-Castillo W, Qato DM, et al. Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: a nested case-control study. Lancet Reg Health Am. 2022;13:100302. https:\/\/doi.org\/10.1016\/j.lana.2022.100302.","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"1007_CR32","first-page":"1","volume":"23","author":"S Babalonis","year":"2015","unstructured":"Babalonis S, Walsh SL. Warnings unheeded: the risks of co-prescribing opioids and benzodiazepines. Pain Clin Updates. 2015;23(6):1\u20137.","journal-title":"Pain Clin Updates"},{"key":"1007_CR33","unstructured":"Center for Behavioral Health Statistics and Quality. The TEDS report: substance abuse treatment admissions for abuse of benzodiazepines. Substance Abuse and Mental Health Services Administration; 2011."},{"key":"1007_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. https:\/\/doi.org\/10.1136\/bmj.j760.","journal-title":"BMJ"},{"key":"1007_CR35","unstructured":"US Food & Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or coughmedicines with benzodiazepines; requires its strongest warning. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or. Accessed 20 Aug 2025."},{"key":"1007_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102584","volume":"38","author":"SA Taha","year":"2024","unstructured":"Taha SA, Westra JR, Tacker DH, Raji MA, Kuo YF. Trends in co-prescribed opioids and benzodiazepines, non-prescribed opioids and benzodiazepines, and schedule-I drugs in the United States, 2013 to 2019. Prev Med Rep. 2024;38:102584. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102584.","journal-title":"Prev Med Rep"},{"key":"1007_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpsychires.2020.05.020","volume":"128","author":"RK McHugh","year":"2020","unstructured":"McHugh RK, Peckham AD, Bjorgvinsson T, Korte FM, Beard C. Benzodiazepine misuse among adults receiving psychiatric treatment. J Psychiatr Res. 2020;128:33\u20137. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.020.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"1007_CR38","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/pm\/pny179","volume":"20","author":"BJH Yarborough","year":"2019","unstructured":"Yarborough BJH, Stumbo SP, Stoneburner A, et al. Correlates of benzodiazepine use and adverse outcomes among patients with chronic pain prescribed long-term opioid therapy. Pain Med. 2019;20(6):1148\u201355. https:\/\/doi.org\/10.1093\/pm\/pny179.","journal-title":"Pain Med"},{"issue":"2","key":"1007_CR39","first-page":"173","volume":"17","author":"N Vadivelu","year":"2017","unstructured":"Vadivelu N, Kai AM, Kodumudi G, Babayan K, Fontes M, Burg MM. Pain and psychology\u2014a reciprocal relationship. Ochsner J. 2017;17(2):173\u201380.","journal-title":"Ochsner J"},{"key":"1007_CR40","unstructured":"Pfizer Inc. NEURONTIN\u00ae (gabapentin). Full Prescribing Information. Pfizer Inc.; 2020."},{"issue":"6","key":"1007_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.18553\/jmcp.2003.9.6.559","volume":"9","author":"A Mack","year":"2003","unstructured":"Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559\u201368. https:\/\/doi.org\/10.18553\/jmcp.2003.9.6.559.","journal-title":"J Manag Care Pharm"},{"key":"1007_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1583415","volume":"16","author":"K Linnet","year":"2025","unstructured":"Linnet K, Runolfsson BPL, Sigurdsson JA, Gudmundsson LS. Incident gabapentin prescribing associated with opioid and benzodiazepine\/Z-drug prescribing\u2014a population-based longitudinal study in primary care. Front Pharmacol. 2025;16:1583415. https:\/\/doi.org\/10.3389\/fphar.2025.1583415.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1007_CR43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.5665\/sleep.4808","volume":"38","author":"SJ Chen","year":"2015","unstructured":"Chen SJ, Yeh CM, Chao TF, et al. The use of benzodiazepine receptor agonists and risk of respiratory failure in patients with chronic obstructive pulmonary disease: a nationwide population-based case-control study. Sleep. 2015;38(7):1045\u201350. https:\/\/doi.org\/10.5665\/sleep.4808.","journal-title":"Sleep"},{"key":"1007_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01513","volume":"9","author":"SH Wang","year":"2018","unstructured":"Wang SH, Chen WS, Tang SE, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2018;9:1513. https:\/\/doi.org\/10.3389\/fphar.2018.01513.","journal-title":"Front Pharmacol"},{"key":"1007_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108061","volume":"117","author":"RK McHugh","year":"2020","unstructured":"McHugh RK, Votaw VR, Taghian NR, Griffin ML, Weiss RD. Benzodiazepine misuse in adults with alcohol use disorder: prevalence, motives and patterns of use. J Subst Abuse Treat. 2020;117:108061. https:\/\/doi.org\/10.1016\/j.jsat.2020.108061.","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl","key":"1007_CR46","first-page":"64","volume":"54","author":"EM Sellers","year":"1993","unstructured":"Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry. 1993;54(Suppl):64\u201375.","journal-title":"J Clin Psychiatry"},{"key":"1007_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107261","volume":"111","author":"SW Terman","year":"2020","unstructured":"Terman SW, Aubert CE, Hill CE, et al. Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study. Epilepsy Behav. 2020;111:107261. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107261.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1007_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","volume":"49","author":"CM Jones","year":"2015","unstructured":"Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493\u2013501. https:\/\/doi.org\/10.1016\/j.amepre.2015.03.040.","journal-title":"Am J Prev Med"},{"key":"1007_CR49","unstructured":"US Food & Drug Administration. FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class Includes potential for abuse, addiction, and other serious risks. https:\/\/www.fda.gov\/media\/142368\/download. Accessed 12 Nov 2025."},{"issue":"Suppl 2","key":"1007_CR50","first-page":"28","volume":"66","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28\u201333.","journal-title":"J Clin Psychiatry"},{"key":"1007_CR51","unstructured":"Cleveland Clinic. What\u2019s the difference between dependence and addiction? https:\/\/health.clevelandclinic.org\/addiction-vs-dependence. Accessed 8 Oct 2025."},{"key":"1007_CR52","volume-title":"Misuse of prescription drugs","author":"National Institute on Drug Abuse","year":"2018","unstructured":"National Institute on Drug Abuse. Misuse of prescription drugs. Bethesda: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services; 2018."},{"issue":"3","key":"1007_CR53","first-page":"215","volume":"104","author":"P Devenyi","year":"1971","unstructured":"Devenyi P, Wilson M. Barbiturate abuse and addiction and their relationship to alcohol and alcoholism. Can Med Assoc J. 1971;104(3):215\u20138.","journal-title":"Can Med Assoc J"},{"issue":"4","key":"1007_CR54","first-page":"329","volume":"1","author":"F Lopez-Munoz","year":"2005","unstructured":"Lopez-Munoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329\u201343.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1007_CR55","unstructured":"Suddock JT, Kent KJ, Regina AC, Cain MD. Barbiturate toxicity. Treasure Island: StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499875\/. Accessed 8 Oct 2025."},{"issue":"2","key":"1007_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0091-3057(87)90588-0","volume":"27","author":"NA Ator","year":"1987","unstructured":"Ator NA, Griffiths RR. Self-administration of barbiturates and benzodiazepines: a review. Pharmacol Biochem Behav. 1987;27(2):391\u20138. https:\/\/doi.org\/10.1016\/0091-3057(87)90588-0.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"1007_CR57","first-page":"214","volume":"13","author":"CE Griffin 3rd","year":"2013","unstructured":"Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214\u201323.","journal-title":"Ochsner J"},{"issue":"12","key":"1007_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121784","volume":"12","author":"MP Goldschen-Ohm","year":"2022","unstructured":"Goldschen-Ohm MP. Benzodiazepine modulation of GABA(A) receptors: a mechanistic perspective. Biomolecules. 2022;12(12):1784. https:\/\/doi.org\/10.3390\/biom12121784.","journal-title":"Biomolecules"},{"key":"1007_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/toxics9020025","author":"E Sanabria","year":"2021","unstructured":"Sanabria E, Cuenca RE, Esteso MA, Maldonado M. Benzodiazepines: their use either as essential medicines or as toxics substances. Toxics. 2021. https:\/\/doi.org\/10.3390\/toxics9020025.","journal-title":"Toxics"},{"issue":"3","key":"1007_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","volume":"6","author":"A Schmitz","year":"2016","unstructured":"Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin. 2016;6(3):120\u20136. https:\/\/doi.org\/10.9740\/mhc.2016.05.120.","journal-title":"Ment Health Clin"},{"issue":"1","key":"1007_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3988\/jcn.2021.17.1.11","volume":"17","author":"D Kim","year":"2021","unstructured":"Kim D, Kim JM, Cho YW, et al. Antiepileptic drug therapy for status epilepticus. J Clin Neurol. 2021;17(1):11\u20139. https:\/\/doi.org\/10.3988\/jcn.2021.17.1.11.","journal-title":"J Clin Neurol"},{"issue":"6","key":"1007_CR62","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1039\/d2ra06045k","volume":"13","author":"S Teli","year":"2023","unstructured":"Teli S, Teli P, Soni S, Sahiba N, Agarwal S. Synthetic aspects of 1,4- and 1,5-benzodiazepines using o-phenylenediamine: a study of past quinquennial. RSC Adv. 2023;13(6):3694\u2013714. https:\/\/doi.org\/10.1039\/d2ra06045k.","journal-title":"RSC Adv"},{"issue":"5","key":"1007_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012253.pub2","volume":"5","author":"L Song","year":"2018","unstructured":"Song L, Liu F, Liu Y, Zhang R, Ji H, Jia Y. Clonazepam add-on therapy for refractory epilepsy in adults and children. Cochrane Database Syst Rev. 2018;5(5):CD012253. https:\/\/doi.org\/10.1002\/14651858.CD012253.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1007_CR64","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1212\/CPJ.0000000000000992","volume":"11","author":"A Jamil","year":"2021","unstructured":"Jamil A, Levinson N, Gelfand M, Hill CE, Khankhanian P, Davis KA. Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurol Clin Pract. 2021;11(5):e669\u201376. https:\/\/doi.org\/10.1212\/CPJ.0000000000000992.","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"1007_CR65","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/epi.17441","volume":"64","author":"J French","year":"2023","unstructured":"French J, Biton V, Dave H, et al. A randomized phase\u00a02b efficacy study in patients with seizure episodes with a predictable pattern using Staccato\u00ae alprazolam for rapid seizure termination. Epilepsia. 2023;64(2):374\u201385. https:\/\/doi.org\/10.1111\/epi.17441.","journal-title":"Epilepsia"},{"issue":"1","key":"1007_CR66","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12954-025-01310-z","volume":"22","author":"C Morrison","year":"2025","unstructured":"Morrison C, Natale I, Branchflower A, Harvey C, Lundin RM. Harm reduction approaches for the use of benzodiazepines: a scoping review. Harm Reduct J. 2025;22(1):162. https:\/\/doi.org\/10.1186\/s12954-025-01310-z.","journal-title":"Harm Reduct J"},{"issue":"6936","key":"1007_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6936.1082","volume":"308","author":"J Strang","year":"1994","unstructured":"Strang J, Griffiths P, Abbey J, Gossop M. Survey of use of injected benzodiazepines among drug users in Britain. BMJ. 1994;308(6936):1082. https:\/\/doi.org\/10.1136\/bmj.308.6936.1082.","journal-title":"BMJ"},{"issue":"12","key":"1007_CR68","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1046\/j.1360-0443.2000.951217858.x","volume":"95","author":"J Ross","year":"2000","unstructured":"Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction. 2000;95(12):1785\u201393. https:\/\/doi.org\/10.1046\/j.1360-0443.2000.951217858.x.","journal-title":"Addiction"},{"issue":"2","key":"1007_CR69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/bcpt.12655","volume":"120","author":"JT Horsfall","year":"2017","unstructured":"Horsfall JT, Sprague JE. The pharmacology and toxicology of the \u2018holy trinity.\u2019 Basic Clin Pharmacol Toxicol. 2017;120(2):115\u20139. https:\/\/doi.org\/10.1111\/bcpt.12655.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1007_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17425255.2020.1721458","volume":"16","author":"R Balyan","year":"2020","unstructured":"Balyan R, Hahn D, Huang H, Chidambaran V. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol. 2020;16(2):125\u201341. https:\/\/doi.org\/10.1080\/17425255.2020.1721458.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1007_CR71","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/pm\/pnv020","volume":"17","author":"LR Webster","year":"2016","unstructured":"Webster LR, Kopecky EA, Smith MD, Fleming AB. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17(6):1112\u201330. https:\/\/doi.org\/10.1093\/pm\/pnv020.","journal-title":"Pain Med"},{"issue":"4","key":"1007_CR72","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/epi.16847","volume":"62","author":"J Cloyd","year":"2021","unstructured":"Cloyd J, Haut S, Carrazana E, Rabinowicz AL. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62(4):846\u201356. https:\/\/doi.org\/10.1111\/epi.16847.","journal-title":"Epilepsia"},{"key":"1007_CR73","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2022. PEP22-07-01-005."},{"issue":"4","key":"1007_CR74","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/bcp.14537","volume":"87","author":"J Hockenhull","year":"2021","unstructured":"Hockenhull J, Amioka E, Black JC, et al. Non-medical use of benzodiazepines and GABA analogues in Europe. Br J Clin Pharmacol. 2021;87(4):1684\u201394. https:\/\/doi.org\/10.1111\/bcp.14537.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1007_CR75","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1111\/epi.18546","volume":"66","author":"LL Ernst","year":"2025","unstructured":"Ernst LL. Drug enforcement administration scheduling negatively impacts patients with epilepsy: a call to action. Epilepsia. 2025;66(9):3578\u201380. https:\/\/doi.org\/10.1111\/epi.18546.","journal-title":"Epilepsia"},{"issue":"5","key":"1007_CR76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152\u20135. https:\/\/doi.org\/10.18773\/austprescr.2015.055.","journal-title":"Aust Prescr"},{"key":"1007_CR77","doi-asserted-by":"crossref","unstructured":"Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;2015(5):CD009652.","DOI":"10.1002\/14651858.CD009652.pub2"},{"key":"1007_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108402","volume":"129","author":"A Hogue","year":"2021","unstructured":"Hogue A, Becker SJ, Wenzel K, et al. Family involvement in treatment and recovery for substance use disorders among transition-age youth: research bedrocks and opportunities. J Subst Abuse Treat. 2021;129:108402. https:\/\/doi.org\/10.1016\/j.jsat.2021.108402.","journal-title":"J Subst Abuse Treat"},{"key":"1007_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.109002","volume":"140","author":"ST Herman","year":"2023","unstructured":"Herman ST, Detyniecki K, O\u2019Hara K, et al. Written seizure action plans for adult patients with epilepsy: distilling insights from emergency action plans for other chronic conditions. Epilepsy Behav. 2023;140:109002. https:\/\/doi.org\/10.1016\/j.yebeh.2022.109002.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1007_CR80","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/epi.17385","volume":"63","author":"SN Misra","year":"2022","unstructured":"Misra SN, Sperling MR, Rao VR, et al. Significant improvements in seizure interval (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. Epilepsia. 2022;63(10):2684\u201393. https:\/\/doi.org\/10.1111\/epi.17385.","journal-title":"Epilepsia"},{"issue":"6","key":"1007_CR81","doi-asserted-by":"publisher","first-page":"639","DOI":"10.18553\/jmcp.2014.20.6.639","volume":"20","author":"J Birt","year":"2014","unstructured":"Birt J, Johnston J, Nelson D. Exploration of claims-based utilization measures for detecting potential nonmedical use of prescription drugs. J Manag Care Spec Pharm. 2014;20(6):639\u201346. https:\/\/doi.org\/10.18553\/jmcp.2014.20.6.639.","journal-title":"J Manag Care Spec Pharm"},{"key":"1007_CR82","unstructured":"United States Department of Justice Drug Enforcement Administration Diversion Control Division. Practitioner\u2019s manual. https:\/\/deadiversion.usdoj.gov\/GDP\/(DEA-DC-071)(EO-DEA226)_Practitioner\u2019s_Manual_(final).pdf. Accessed 27 Aug 2025."},{"key":"1007_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1615079","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang Y, Liang Y. Benzodiazepine-resistant epilepsy: unraveling molecular mechanisms and developing multimodal therapeutic strategies. Front Neurol. 2025;16:1615079. https:\/\/doi.org\/10.3389\/fneur.2025.1615079.","journal-title":"Front Neurol"},{"issue":"11","key":"1007_CR84","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/070674371005501104","volume":"55","author":"N el-Guebaly","year":"2010","unstructured":"el-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? Can J Psychiatry. 2010;55(11):709\u201314. https:\/\/doi.org\/10.1177\/070674371005501104.","journal-title":"Can J Psychiatry"},{"key":"1007_CR85","doi-asserted-by":"publisher","unstructured":"Liu S, O\u2019Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136\u201341. https:\/\/doi.org\/10.15585\/mmwr.mm7034a2.","DOI":"10.15585\/mmwr.mm7034a2"},{"issue":"2","key":"1007_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7020017","volume":"7","author":"J Guina","year":"2018","unstructured":"Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17. https:\/\/doi.org\/10.3390\/jcm7020017.","journal-title":"J Clin Med"},{"key":"1007_CR87","unstructured":"Centers for Disease Control and Prevention. Injecting drugs can give you deadly infections. https:\/\/www.cdc.gov\/vitalsigns\/staph\/pdf\/vs-safe-drug-use_patient.pdf. Accessed 30 Sept 2025."},{"key":"1007_CR88","unstructured":"Government of South Australia. The risks of using drugs. https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/healthy+living\/is+your+health+at+risk\/the+risks+of+using+drugs. Accessed 30 Sept 2025."},{"key":"1007_CR89","unstructured":"American Addiction Centers. Nose damage from drug use: impact of snorting drugs on the nasal passages. https:\/\/americanaddictioncenters.org\/health-complications-addiction\/drugs-nose. Accessed 30 Sept 2025."},{"key":"1007_CR90","unstructured":"Humayun MJ, Samanta D, Carson RP. Clobazam. Treasure Island (FL): StatPearls; 2026."},{"key":"1007_CR91","unstructured":"Lundbeck. Onfi\u00ae (clobazam). Full Prescribing Information. Lundbeck; 2024."},{"key":"1007_CR92","unstructured":"Dhaliwal JS, Rosani A, Saadabadi A. Diazepam. Treasure Island (FL): StatPearls; 2026."},{"key":"1007_CR93","unstructured":"Ghiasi N, Bhansali RK, Marwaha R. Lorazepam. Treasure Island (FL): StatPearls; 2026."},{"key":"1007_CR94","unstructured":"Hospira, Inc. Midazolam injection (midazolam injection). Full Prescribing Information. Hospira, Inc.; 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:12:10Z","timestamp":1789665130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":94,"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01007-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Carrazana is an employee of and has received stock and stock options from Neurelis, Inc. Dr Sirven is an advisor for Neurelis, Inc. Dr Stern is a consultant for Eisai, Jazz, Neurelis, Inc., SK Life Science, and UCB. Dr Gidal is a consultant for Aquestive, Eisai Inc., Jazz, Neurelis, Inc., and SK Life Science; is a member of the End Point Review Committee for Sunovion Pharmaceuticals Inc.; and has a grant\/contract with UCB Inc. Dr Kanner has received honoraria for participation in advisory boards from Neurelis, Inc., and Angelini Pharma and for serving as co-editor-in-chief for the Epilepsy Foundation. Dr Rabinowicz is an employee and has received stock options from Neurelis, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}